Rituximab off-label use for immune diseases: assessing adverse events in a single-centre drug-utilization survey.
Sailler
Laurent
L
Attane
Camille
C
Michenot
Fleur
F
Canonge
Jean-Marie
JM
Rostaing
Lionel
L
Arlet-Suau
Elizabeth
E
Arlet
Philippe
P
Launay
François
F
Montastruc
Jean-Louis
JL
Lapeyre-Mestre
Maryse
M
D000163:Acquired Immunodeficiency Syndrome / Q000188:drug therapy*; D000328:Adult; D000368:Aged; D000911:Antibodies, Monoclonal / Q000009:adverse effects*; D058846:Antibodies, Monoclonal, Murine-Derived; D004348:Drug Labeling; D005260:Female; D006801:Humans; D016867:Immunocompromised Host / Q000187:drug effects; D007155:Immunologic Factors / Q000009:adverse effects*; D008297:Male; D008875:Middle Aged; D000069283:Rituximab; D016896:Treatment Outcome
D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D007155:Immunologic Factors; D000069283:Rituximab